Most studies have found that anillin is overexpressed in diverse tumors, and its expression correlates with cancer progression and poor survival rates (Hall et al., 2005; Suzuki et al., 2005; Wang et al., 2016; Idichi et al., 2017; Zhang et al., 2018). This evidence concerns the gene ANLN and cancer.